Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Archives of Microbiology|April 9, 2023
A newly constructed Agrobacterium-mediated transformation system based on the hisB auxotrophic marker for genetic manipulation in Aspergillus nigerHanh-Dung Thai, Loc Thi Binh Xuan Do, Xuan Thi Nguyen, et al.
Cardiovascular Diabetology|January 11, 2019
Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarctionQutuba G Karwi, Liyan Zhang, Cory S Wagg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)Manish A Shah, Gyorgy Bodoky, Alexander Starodub, et al.
Respiratory Medicine Case Reports|January 6, 2025
A rare case of acute respiratory distress syndrome due to chlorine gas inhalation: Rapid progression with favorable ICU outcomeDung Thai Pham, Bang Ngoc Dao, Dung Tien Nguyen, et al.
Heliyon|February 28, 2023
Efficient control of the fungal pathogens Colletotrichum gloeosporioides and Penicillium digitatum infecting citrus fruits by native soilborne Bacillus velezensis strainsTao Xuan Vu, Tram Bao Tran, Minh Binh Tran, et al.
Biotechnology Letters|April 18, 2023
An efficient Agrobacterium-mediated system based on the pyrG auxotrophic marker for recombinant expression in the filamentous fungus Penicillium rubensVan-Tuan Tran, Hanh-Dung Thai, Tao Xuan Vu, et al.
Diabetes, Obesity & Metabolism|December 29, 2017
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trialJeremy Pettus, Dominic Reeds, Tricia S Cavaiola, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, et al.
Scientific Reports|June 30, 2022
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinomaAkira Ooki, Taroh Satoh, Kei Muro, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b studyAkie Kimura Yoshikawa, Kensei Yamaguchi, Kei Muro, et al.
Pageof 4